Bio-Techne logo

Bio-Techne Stock

StockStock
ISIN: US09073M1045
Ticker: TECH
US09073M1045
TECH

Price

Historical dividends and forecast

All dividend data

Bio-Techne has so far distributed $0.24 in 2024. The next dividend will be paid on 22.11.2024


$0.797

CHART BY

Frequently asked questions

What is Bio-Techne's market capitalization?

The market capitalization of Bio-Techne is $11.82B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Bio-Techne's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Bio-Techne is 79.15. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Bio-Techne?

Bio-Techne's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.94. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Bio-Techne's stock?

Currently, 12 analysts cover Bio-Techne's stock, with a consensus target price of $83.64. Analyst ratings provide insights into the stock's expected performance.

What is Bio-Techne's revenue over the trailing twelve months?

Over the trailing twelve months, Bio-Techne reported a revenue of $1.17B.

Is Bio-Techne paying dividends?

Yes, Bio-Techne is paying dividends. The next payment is scheduled for 22.11.2024, with an expected amount of .

What is the EBITDA for Bio-Techne?

Bio-Techne's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $361.33M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Bio-Techne?

Bio-Techne has a free cash flow of $194.58M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Bio-Techne's stock?

The 5-year beta for Bio-Techne is 1.27. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Bio-Techne have, and what sector and industry does it belong to?

Bio-Techne employs approximately 3,100 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Bio-Techne's shares?

The free float of Bio-Techne is 157.24M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$11.82B

5Y beta

 
1.27

EPS (TTM)

 
$0.94

Free Float

 
157.24M

P/E ratio (TTM)

 
79.15

Revenue (TTM)

 
$1.17B

EBITDA (TTM)

 
$361.33M

Free Cashflow (TTM)

 
$194.58M

Pricing

1D span
$73.57$76.47
52W span
$60.53$85.57

Analyst Ratings

The price target is $83.64 and the stock is covered by 12 analysts.

Buy

9

Hold

2

Sell

1

Information

Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.

3,100

Biotechnology & Drugs

Health Care

Identifier

ISIN

US09073M1045

Primary Ticker

TECH

Knockouts

Join the conversation